Veradermics, Inc
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
MANE$148.44+3.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets (unaudited)
Condensed Consolidated Balance Sheets
| As of March 31, | As of December 31, | |
|---|---|---|
| (in thousands, except share and per share amounts) | 2026 | 2025 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $168,412 | $21,766 |
| Marketable securities at fair value | 222,385 | 120,096 |
| Prepaid expenses and other current assets | 6,272 | 10,632 |
| Total current assets | 397,069 | 152,494 |
| Long-term assets: | ||
| Property, plant and equipment, net | 21 | 22 |
| Right-of-use asset and other long-term assets | 266 | 103 |
| Total non-current assets | 287 | 125 |
| Total assets | $397,356 | $152,619 |
| Liabilities and stockholders’ equity (deficit) | ||
| Current liabilities: | ||
| Accounts payable | $1,071 | $2,126 |
| Accrued expenses | 5,606 | 6,979 |
| Other current liabilities and lease liabilities | 39 | 47 |
| Total current liabilities | 6,716 | 9,152 |
| Lease liabilities - non-current | — | 4 |
| Total liabilities | 6,716 | 9,156 |
| Commitments and contingencies (Note 8) | ||
| Redeemable convertible preferred stock: | ||
| Series A preferred stock, $0.00001 par value, 12,865,375 shares authorized, issued and outstanding with an aggregate liquidation preference of $37,238 as of December 31, 2025, net of issuance costs | — | 36,860 |
| Series B preferred stock, $0.00001 par value, 62,245,805 shares authorized, issued and outstanding with an aggregate liquidation preference of $85,376 as of December 31, 2025, net of issuance costs | — | 78,903 |
| Series C preferred stock, $0.00001 par value, 118,682,683 shares authorized, issued and outstanding with an aggregate liquidation preference of $154,815 as of December 31, 2025, net of issuance costs | — | 150,563 |
| Subscription receivable | — | (1,849) |
| Stockholders’ equity (deficit) | ||
| Preferred stock, $0.00001 par value, 25,000,000 and 0 shares authorized as of March 31, 2026 and December 31, 2025, respectively and 0 shares issued or outstanding as of March 31, 2026 and December 31, 2025, respectively | — | — |
| As of March 31, | As of December 31, | |
|---|---|---|
| (in thousands, except share and per share amounts) | 2026 | 2025 |
| Common stock, $0.00001 par value, 200,000,000 and 267,466,797 shares authorized as of March 31, 2026 and December 31, 2025, respectively and 37,340,290 and 749,760 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 1 | 1 |
| Additional paid-in capital | 543,044 | 2,346 |
| Subscription receivable | (1,228) | — |
| Accumulated other comprehensive income | (524) | 60 |
| Accumulated deficit | (150,653) | (123,421) |
| Total stockholders’ equity (deficit) | 390,640 | (121,014) |
| Total liabilities, redeemable convertible preferred stock, and stockholders’ equity (deficit) | $397,356 | $152,619 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.